251 related articles for article (PubMed ID: 18936689)
21. Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy.
Goldstein NS; Decker D; Severson D; Schell S; Vicini F; Margolis J; Dekhne NS
Cancer; 2007 Oct; 110(8):1687-96. PubMed ID: 17722109
[TBL] [Abstract][Full Text] [Related]
22. p53 expression in tumor-stromal fibroblasts is closely associated with the nodal metastasis and outcome of patients with invasive ductal carcinoma who received neoadjuvant therapy.
Hasebe T; Tamura N; Okada N; Hojo T; Akashi-Tanaka S; Shimizu C; Tsuda H; Shibata T; Sasajima Y; Iwasaki M; Kinoshita T
Hum Pathol; 2010 Feb; 41(2):262-70. PubMed ID: 19836055
[TBL] [Abstract][Full Text] [Related]
23. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
McKenney JK; Balzer BL; Longacre TA
Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150
[TBL] [Abstract][Full Text] [Related]
24. Extensive retraction artifact correlates with lymphatic invasion and nodal metastasis and predicts poor outcome in early stage breast carcinoma.
Acs G; Dumoff KL; Solin LJ; Pasha T; Xu X; Zhang PJ
Am J Surg Pathol; 2007 Jan; 31(1):129-40. PubMed ID: 17197929
[TBL] [Abstract][Full Text] [Related]
25. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.
Tanei T; Morimoto K; Shimazu K; Kim SJ; Tanji Y; Taguchi T; Tamaki Y; Noguchi S
Clin Cancer Res; 2009 Jun; 15(12):4234-41. PubMed ID: 19509181
[TBL] [Abstract][Full Text] [Related]
26. [Neoadjuvant systemic therapy in patients with operable primary breast cancer: more benefits than breast-conserving therapy].
Straver ME; van Adrichem JC; Rutgers EJ; Rodenhuis S; Linn SC; Loo CE; Gilhuijs KG; Oldenburg HS; Wesseling J; Russell NS; Antonini N; Vrancken Peeters MT
Ned Tijdschr Geneeskd; 2008 Nov; 152(46):2519-25. PubMed ID: 19055260
[TBL] [Abstract][Full Text] [Related]
27. [Micrometastatic disease and residual axillary disease. Breast cancer as an example Alct].
Penault-Llorca F; Mishellany F
Cancer Radiother; 2006 Nov; 10(6-7):338-42. PubMed ID: 16973394
[TBL] [Abstract][Full Text] [Related]
28. Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer.
Rouzier R; Pusztai L; Garbay JR; Delaloge S; Hunt KK; Hortobagyi GN; Berry D; Kuerer HM
Cancer; 2006 Oct; 107(7):1459-66. PubMed ID: 16948128
[TBL] [Abstract][Full Text] [Related]
29. The pathologic complete response open question in primary therapy.
Marchiò C; Sapino A
J Natl Cancer Inst Monogr; 2011; 2011(43):86-90. PubMed ID: 22043049
[TBL] [Abstract][Full Text] [Related]
30. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.
Gralow JR; Burstein HJ; Wood W; Hortobagyi GN; Gianni L; von Minckwitz G; Buzdar AU; Smith IE; Symmans WF; Singh B; Winer EP
J Clin Oncol; 2008 Feb; 26(5):814-9. PubMed ID: 18258991
[TBL] [Abstract][Full Text] [Related]
31. Combined use of MRI and PET to monitor response and assess residual disease for locally advanced breast cancer treated with neoadjuvant chemotherapy.
Chen X; Moore MO; Lehman CD; Mankoff DA; Lawton TJ; Peacock S; Schubert EK; Livingston RB
Acad Radiol; 2004 Oct; 11(10):1115-24. PubMed ID: 15530804
[TBL] [Abstract][Full Text] [Related]
32. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy.
Jeruss JS; Mittendorf EA; Tucker SL; Gonzalez-Angulo AM; Buchholz TA; Sahin AA; Cormier JN; Buzdar AU; Hortobagyi GN; Hunt KK
J Clin Oncol; 2008 Jan; 26(2):246-52. PubMed ID: 18056680
[TBL] [Abstract][Full Text] [Related]
33. The effect of neoadjuvant chemotherapy on histologic grade, hormone receptor status, and HER2/neu status in breast carcinoma.
Adams AL; Eltoum I; Krontiras H; Wang W; Chhieng DC
Breast J; 2008; 14(2):141-6. PubMed ID: 18248553
[TBL] [Abstract][Full Text] [Related]
34. Breast carcinoma grading, estimation of tumor size, axillary lymph node status, staging, and nottingham prognostic index scoring on mastectomy specimens.
Ahmad Z; Khurshid A; Qureshi A; Idress R; Asghar N; Kayani N
Indian J Pathol Microbiol; 2009; 52(4):477-81. PubMed ID: 19805950
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant systemic therapy and the surgical management of breast cancer.
Waljee JF; Newman LA
Surg Clin North Am; 2007 Apr; 87(2):399-415, ix. PubMed ID: 17498534
[TBL] [Abstract][Full Text] [Related]
36. Usefulness of preoperative multidetector-row computed tomography in evaluating the extent of invasive lobular carcinoma in patients with or without neoadjuvant chemotherapy.
Shien T; Akashi-Tanaka S; Yoshida M; Hojo T; Iwamoto E; Miyagawa K; Kinoshita T
Breast Cancer; 2009; 16(1):30-6. PubMed ID: 18360805
[TBL] [Abstract][Full Text] [Related]
37. Tumor budding in tumor invasive front predicts prognosis and survival of patients with esophageal squamous cell carcinomas receiving neoadjuvant chemotherapy.
Miyata H; Yoshioka A; Yamasaki M; Nushijima Y; Takiguchi S; Fujiwara Y; Nishida T; Mano M; Mori M; Doki Y
Cancer; 2009 Jul; 115(14):3324-34. PubMed ID: 19452547
[TBL] [Abstract][Full Text] [Related]
38. Biological markers of risk in nipple aspirate fluid are associated with residual cancer and tumour size.
Sauter ER; Ehya H; Babb J; Diamandis E; Daly M; Klein-Szanto A; Sigurdson E; Hoffman J; Malick J; Engstrom PF
Br J Cancer; 1999 Dec; 81(7):1222-7. PubMed ID: 10584885
[TBL] [Abstract][Full Text] [Related]
39. Computer-aided detection applied to breast MRI: assessment of CAD-generated enhancement and tumor sizes in breast cancers before and after neoadjuvant chemotherapy.
Demartini WB; Lehman CD; Peacock S; Russell MT
Acad Radiol; 2005 Jul; 12(7):806-14. PubMed ID: 16039534
[TBL] [Abstract][Full Text] [Related]
40. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
